Another trial, CheckMate 069, recorded the hazard ratio for death or progression of disease for combined versus single-agent immunotherapy for BRAF wild-type as 0.40 (95% CI: 0.23 to 0.68, p < 0.001) and BRAF-mutant as 0.38 (95% CI: 0.15 to 1.00) melanoma patients, underscoring the survival benefit with combination checkpoint inhibition [53]. The gene discussed is BRAF; the disease is melanoma.